Loeb & Loeb Represents Insud Pharma in Acquisition of Agile Therapeutics

Loeb & Loeb represented Insud Pharma, a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries, in its acquisition of Agile Therapeutics, a women's health care company.

The former holders of Agile common stock voted to approve the acquisition at a special meeting of stockholders on August 22, 2024. Upon closing of the acquisition, former shareholders of Agile became entitled to receive $1.52 per share in cash, net of assumed liabilities and estimated transaction costs for an approximate total enterprise value of $45 million.

Insud completed its acquisition of Agile through the merger of an indirect, wholly owned subsidiary of Insud with and into Agile, with Agile continuing as the surviving company and becoming an indirect subsidiary of Insud, pursuant to a definitive merger agreement dated as of June 25, 2024. With the completion of the transaction, Agile will no longer be listed on any public market.

The Loeb team that represented Insud Pharma was led by Loeb & Loeb Co-Chair Mitch Nussbaum and Capital Markets & Corporate partner Norwood Beveridge and included Executive Compensation & Employee Benefits partner Marina Casani; Finance associate Adam Rose; and Tax partner Shahrooz Shahnavaz and associate Simoné Hovsepian.

To read more, please see Agile Therapeutics’ press release.